Cargando…

The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1

We investigated the effect of the sodium glucose cotransporter-2 inhibitor (SGLT-2i) luseogliflozin on skeletal muscle. Eight-week-old mice were fed a standard diet or the standard diet with added luseogliflozin for 8 weeks. The mice were divided into the following four genotype/dietary groups: Db/m...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamura, Takuro, Hashimoto, Yoshitaka, Osaka, Takafumi, Fukuda, Takuya, Hamaguchi, Masahide, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667382/
https://www.ncbi.nlm.nih.gov/pubmed/31379410
http://dx.doi.org/10.3164/jcbn.18-114
_version_ 1783440024777261056
author Okamura, Takuro
Hashimoto, Yoshitaka
Osaka, Takafumi
Fukuda, Takuya
Hamaguchi, Masahide
Fukui, Michiaki
author_facet Okamura, Takuro
Hashimoto, Yoshitaka
Osaka, Takafumi
Fukuda, Takuya
Hamaguchi, Masahide
Fukui, Michiaki
author_sort Okamura, Takuro
collection PubMed
description We investigated the effect of the sodium glucose cotransporter-2 inhibitor (SGLT-2i) luseogliflozin on skeletal muscle. Eight-week-old mice were fed a standard diet or the standard diet with added luseogliflozin for 8 weeks. The mice were divided into the following four genotype/dietary groups: Db/m mice without SGLT-2i, Db/m mice with SGLT-2i inhibitor, Db/Db without SGLT-2i, and Db/Db with SGLT-2i. Among the mice with and without SGLT-2i, the ratio of soleus and plantaris muscle to body weight in the Db/Db mice was significantly lower than that in the Db/m mice. The cross-sectional area of soleus muscle in the Db/Db mice without SGLT-2i was significantly higher than that in the Db/Db mice with SGLT-2i. The expression of foxo1 in soleus muscle of the Db/Db mice was significantly higher than that of the Db/m mice, and the foxo1 expression of the Db/Db mice with SGLT-2i was significantly lower than that of the mice without SGLT-2i. The fluorescence intensity of foxo1 in the Db/Db mice fed SGLT-2i was significantly lower than that in the Db/Db mice without SGLT-2i. The administration of luseogliflozin resulted in the suppression of both the increased foxo1 expression and the reduced muscle cross-sectional area in the soleus muscle of Db/Db mice.
format Online
Article
Text
id pubmed-6667382
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher the Society for Free Radical Research Japan
record_format MEDLINE/PubMed
spelling pubmed-66673822019-08-02 The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1 Okamura, Takuro Hashimoto, Yoshitaka Osaka, Takafumi Fukuda, Takuya Hamaguchi, Masahide Fukui, Michiaki J Clin Biochem Nutr Original Article We investigated the effect of the sodium glucose cotransporter-2 inhibitor (SGLT-2i) luseogliflozin on skeletal muscle. Eight-week-old mice were fed a standard diet or the standard diet with added luseogliflozin for 8 weeks. The mice were divided into the following four genotype/dietary groups: Db/m mice without SGLT-2i, Db/m mice with SGLT-2i inhibitor, Db/Db without SGLT-2i, and Db/Db with SGLT-2i. Among the mice with and without SGLT-2i, the ratio of soleus and plantaris muscle to body weight in the Db/Db mice was significantly lower than that in the Db/m mice. The cross-sectional area of soleus muscle in the Db/Db mice without SGLT-2i was significantly higher than that in the Db/Db mice with SGLT-2i. The expression of foxo1 in soleus muscle of the Db/Db mice was significantly higher than that of the Db/m mice, and the foxo1 expression of the Db/Db mice with SGLT-2i was significantly lower than that of the mice without SGLT-2i. The fluorescence intensity of foxo1 in the Db/Db mice fed SGLT-2i was significantly lower than that in the Db/Db mice without SGLT-2i. The administration of luseogliflozin resulted in the suppression of both the increased foxo1 expression and the reduced muscle cross-sectional area in the soleus muscle of Db/Db mice. the Society for Free Radical Research Japan 2019-07 2019-05-18 /pmc/articles/PMC6667382/ /pubmed/31379410 http://dx.doi.org/10.3164/jcbn.18-114 Text en Copyright © 2019 JCBN http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Okamura, Takuro
Hashimoto, Yoshitaka
Osaka, Takafumi
Fukuda, Takuya
Hamaguchi, Masahide
Fukui, Michiaki
The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
title The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
title_full The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
title_fullStr The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
title_full_unstemmed The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
title_short The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
title_sort sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in db/db mice by suppressing the expression of foxo1
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667382/
https://www.ncbi.nlm.nih.gov/pubmed/31379410
http://dx.doi.org/10.3164/jcbn.18-114
work_keys_str_mv AT okamuratakuro thesodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT hashimotoyoshitaka thesodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT osakatakafumi thesodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT fukudatakuya thesodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT hamaguchimasahide thesodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT fukuimichiaki thesodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT okamuratakuro sodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT hashimotoyoshitaka sodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT osakatakafumi sodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT fukudatakuya sodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT hamaguchimasahide sodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1
AT fukuimichiaki sodiumglucosecotransporter2inhibitorluseogliflozincansuppressmuscleatrophyindbdbmicebysuppressingtheexpressionoffoxo1